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Acute kidney injury (AKI) is becoming more prevalent among hospitalized children, its etiologies are shifting, and new treatment
modalities are evolving; however, diarrhea-associated hemolytic uremic syndrome (D+HUS) remains the most common primary
disease causing AKI in young children. Little has been published about acute renal replacement therapy (ARRT) and its challenges
inthispopulation.Wedescribe oursinglecenter’s experience managing134pediatric patientswithD+HUS outofwhom58(43%)
required ARRT over the past 16 years. In our cohort, all but one patient were started on peritoneal dialysis (PD). Most patients, 47
(81%), received acute PD on a pediatric inpatient ward. The mostcommonrecorded complications in our cohort were peritoneal
ﬂuid leaks 13 (22%), peritonitis 11 (20%),and catheter malfunction 5 (9%). Nine patients (16%) needed surgical revision of their
PD catheters. There were no bleeding events related to PD despite a mean platelets count of 40.9 (±23.5)×103/mm3 and rare use
ofplatelets infusions.Despite its methodological limitations,this paper adds to the limited body of evidence supporting the use of
acute PD as the primary ARRT modality in children with D+HUS.
1.Introduction
The incidence of acute kidney injury (AKI, previously
called acute renal failure) in children is not well deﬁned,
however, a number of recent studies suggest that it is
increasing. This observation may be related to the changing
etiology of AKI in children particularly in the tertiary care
pediatric care hospital setting. Primary renal disease used to
account for the majority of hospitalized children with AKI,
whereas now the leading cause for AKI in this population
ismultifactorialincludingischemic/hypoxicandnephrotoxic
injury secondary to primary conditions such as prematurity,
postcardiac surgery, or bone marrow transplantation. The
lack of a well-accepted universal deﬁnition of AKI has been
one of the major hurtles for researchers trying to establish
incidence and etiology of AKI in children, however, the
recent validation of the pediatric RIFLE criteria promises to
oﬀer a solution to this problem. RIFLE criteria (R risk for
renal dysfunction, I injury to the kidney, F failure of kidney
function, L loss of kidney function, and E end-stage renal
disease) is a standardized classiﬁcation method for AKI in
adults which has been adapted for and validated in pediatric
patients as pRIFLE [1–3].
Despite the shift in the most common etiologies for
AKI in hospitalized children from primary kidney disease
to injury secondary to nonrenal diseases, diarrhea-associated
hemolytic uremic syndrome is still considered the most
common primary disease causing acute kidney injury in
young children [4]. Currently, there is no eﬀectivepreventive
or speciﬁc treatment for this disease leaving symptomatic
and supportive treatments as the main management options
for children with D+HUS [5, 6]. Acute renal replacement
therapy (ARRT) is frequently required in the acute phase of
D+HUS. Older published series have reported that ARRT2 International Journal of Nephrology
is needed in up to 100% of patients; however, more recent
studies report that it is required in about 40%–60% of chil-
dren with D+HUS [5, 7]. All available ARRT modalities are
considered equally eﬀective in the management of children
with D+HUS although peritoneal dialysis (PD) has been
mentioned to potentially enhance clearance of plasminogen
activator inhibitor 1, therefore facilitating renal recovery
[8]. Available literature supporting any one speciﬁc AART
modality and even sharing practice experience performing
ARRT in children with D+HUS is very limited.
We recently reviewed patients treated for D+HUS in our
center to calculate the incidence of childhood D+HUS in
Southern Alberta, a region previously shown to be endemic
for D+HUS (in press). The objective in this current paper is
to summarize and share our single center’s experience with
ARRT in children with D+HUS over the past 16 years.
2.Methods
2.1. Patient Recruitment and Inclusion Criteria. Institutional
ethics approval was obtained for this study from the Univer-
sity of Calgary. Alberta Children’s Hospital (ACH) is a sole
tertiary care pediatric referral center providing care for 1.6
million inhabitants of Southern Alberta, Canada.
An electronic database search for all cases of D+HUS
documented at ACH from March 1st, 1994 to March 31st,
2010 was conducted. Charts of identiﬁed patients were re-
viewed to conﬁrm the diagnosis of D+HUS based on the
following criteria: history of diarrhea-associated with in-
travascular hemolytic anemia (hemoglobin <105gm/L with
schistocytes), thrombocytopenia (platelets <150 × 109/L),
and evidenceof renal injury (serumcreatinine concentration
a b o v et h e9 5 t hp e r c e n t i l ef o ra g eo r>10 erythrocytes per
high-power ﬁeld on light microscopy of a urine sample).
Chart documentation of all 3 criteria was required to
conﬁrm a case of D+HUS. Patients younger than 18 years
at diagnosis were included. Patients with atypical hemolytic
uremic syndrome (HUS) such as inherited forms of HUS
and HUS secondary to organisms other than Shiga-like toxin
producing E.coli (STEC) were excluded.
2.2. Acute Renal Replacement Therapy. The need for ARRT
was assessed by the attending nephrologist in a case-by-case
manner for each one of the patients included in this cohort.
Nonspeciﬁc indication for ARRT in the context of AKI were
applied, the most common being progressive oligoanuria
and rapid metabolic deterioration secondary to AKI (rapidly
raising urea, creatinine, potassium, or progressive metabolic
acidosis). While these indications are nonspeciﬁc and strict
parameters have not been adopted, the general consensus
i no u rc e n t e ri st h a tA R R Ts h o u l db eo ﬀered early. In cases
where patients were not oﬀered ARRT during their acute
illness, the attending nephrologist felt that there was no need
for it based on the general criteria mentioned above.
Acute renal replacement modalities available in our
center include PD, intermittent hemodialysis (IHD), or con-
tinuous venovenous hemoﬁltration with or without dialysis
(CVVH ± D). The preferred choice for D+HUS patients in
our centeris PD howeverthe choice is made by the attending
pediatric nephrologist in a case by case manner. Cook spiral
double cuﬀed Tenckhoﬀ peritoneal dialysis catheters are
usually used in our center; however, straight and other types
of catheters are available. An omentenctomy is not routinely
performed at the initial insertion of a Tenckhoﬀ catheter but
is always done during catheter revisions performed due to
technical failure of PD. The preferred access for CVVH in
our institution is a temporary internal jugular line usually
placed by the ICU attending physician or occasionally by
the interventional radiologist. Urgently needed permanent
hemodialysis lines for IHD are usually placed by the attend-
ing general surgeon or the interventional radiologist in the
operating room.
PD is routinely performed on the general pediatric inpa-
tient ward by appropriately trained nurses, whereas CVVH
requires admission to the ICU. IHD can be performed in the
hemodialysis unit; however, during the acute phase, patients
with D+HUS are frequently hemodinamically or neurologi-
cally unstable enough to require ICU care.
2.3. Data Collection. Data was obtained from medical charts
of identiﬁed patients and included age at presentation,
gender, highest creatinine level, lowest platelet count, ARRT
modality, duration of anuria, duration of ARRT, technical
challenges, and complications related to ARRT. Outcome
data collected included documentation of residual chronic
renal failure, proteinuria, and hypertension at last follow-up
visit. Patients were followed for a minimum 1 year and up to
14 years after presentation.
3.Results
After completion of the chart review, 134 children were
conﬁrmed to have been treated for D+HUS at the Alberta
Children’s Hospital from April 1994 to March 2010; ﬁfty
eight of them (43%), required ARRT in the acute phase of
their management. Characteristics of these patients as well
as the rest of the patients and ARRT details are presented
in Table 1. Outcome parameters for patients who required
ARRT and those who did not are shown in Table 2.
Fifty four patents (93%) of the total 58 who required
ARRT were managed exclusively by PD. The remaining 4
patients were managed with PD and an additional modality:
one patient who was septic and hemodynamically unstable
on admission was started on CVVH in the ICU and then
transitioned to PD after 5 days. The other 3 were initiated on
PD but were temporarily switched to CVVHD or IHD due
to severe peritoneal ﬂuid leak, bowel necrosis, and develop-
ment of a pleura-peritoneal communication with a pleural
eﬀusion.
One patient was diagnosed with bowel perforation while
on PD due to feculent PD eﬄuent.An urgent left hemicolec-
tomyandresectionatthehepaticﬂexure wasperformed after
whichCVVHwasattemptedbutfailedbecauseofaninability
toestablish adequatevascular access. The patient successfully
resumed PD and received intraperitoneal antibiotics for
treatment of peritonitis caused by the bowel perforation.International Journal of Nephrology 3
Table 1: Patient characteristics and ARRT details.
Number of patients (n)5 8
Male/Female 25/34
Highest creatinine, mean (±SD), µmol/L 261.3 (±240.1)
Lowest platelet count, mean (±SD), ×103/mm3 40.9 (±23.5)
Patients that received platelets transfusion 3 (5%) Mean
duration of anuria (±SD), days 8.47 (±8.9)
Duration of RRT (±SD), days 20 (±32.4)
Duration of admission(±SD) days 23.8 (±11.6)
Peritoneal ﬂuid leak 13 (22%)
PD catheter malfunction 5 (9%)
Pleuro-peritoneal communication and leak 2 (3%)
PD catheter surgical revisions 9 (16%)
Bleeding events 0
Patients treated for suspected peritonitis 11 (20%)
Patients that required ICU admission 11 (20%)
Mortality 1 (2%)
Table 2: Outcomes after ARRT for D+HUS.
Number of patients (n)5 8
Patients with GFR <80mL/min/1.73m2 7 (12%)
Patients with GFR <40mL/min/1.73m2 1(2%)
Hypertensive at followup 3 (5%)
Proteinuria 18 (31%)
Among the 4 patients who were managed by CVVH or
IHD in our cohort, 3 vascular access catheters clotted or
did not function after insertion. The only death among the
patients who required ARRT, and in fact among all 134
patients with D+HUS, was caused by an episode of massive
gastrointestinal bleeding due to bowel necrosis.
4.Discussion
Diarrhea-associated hemolytic uremic syndrome is the most
common primary disease causing acute kidney injury in
children and among hospitalized children; it is second only
to ischemic/nephrotoxic injury as a cause for acute kidney
injury [4].
The prognosis of D+HUS has improved dramatically
since the disease was ﬁrst reported mostly due to the now
widespread availability of acute renal replacement therapy
in children [7]. Indications for initiation of ARRT in
children with D+HUS are nonspeciﬁc, for the management
of oligoanuria, metabolic acidosis, and electrolyte abnor-
malities. Eﬀective management of these complications can
be achieved by all available methods of ARRT, including
hemodialysis and hemoﬁltration; however, PD is in many
centers the preferred ARRT modality for children with
D+HUS [6, 8]. Our experience reported here supports this
practice by demonstrating that the vast majority of children
with D+HUS requiring ARRT can be safely and successfully
managed with acute PD performed on a pediatric ward
after surgical insertion of a PD catheter. The most common
technical diﬃculty associated with this modality in our
cohort was peritoneal ﬂuid leaking around the catheter
followed by catheter malfunction which did not always
require surgical revision of the catheter. In the majority of
cases, these complications did not result in discontinuation
or change of modality. Peritoneal ﬂuid leaks, for example,
were in most cases successfully managed by temporarily
reducing the dwell volumes.
Despite the profound thrombocytopenia experienced by
themajority ofthepatients,plateletstransfusion werealmost
never used, and bleeding events associated with the surgical
insertion of the PD catheter did not occur. This was also
shown by a recent retrospective study, which found no
bleeding after insertion of PD catheters in children with
D+HUS, with or without platelets transfusions [9].
Sepsis and severe gastrointestinal injury such as bowel
perforation in patients with D+HUS have been mentioned
as possible indications for selecting a diﬀerent modality of
ARRT [10]. One patient from our cohort was successfully
managed with PD even after bowel perforation requiring
emergency hemicolectomy. In fact, PD allowed for a very
rapid diagnosis of the perforation, prompt surgical man-
agement, resumption of PD, and antibiotic treatment of
the intra-abdominal infection. Two additional patients in
our cohort that were on PD when they developed bowel
obstruction secondary to intestinal strictures were managed
conservatively without changing their ARRT.
Patients who are slow to recover their kidney function or
require chronic dialysis can choose to continue with home
PD using the original PD catheter that was inserted during
t h ea c u t ep h a s eo ft h e i rD + H US. In our cohort, there were
two such patients that continued on chronic home PD for 93
and 240 days, respectively, before regaining enough function
to be able to come oﬀ dialysis.
Most of our patients did not require admission to the
ICU and were managed on a regular pediatric ward by
nursing staﬀ that had previous training in PD. In our center,
selection of other ARRT modalities would have led to many
more days spent in the ICU. The availability of IHD and
CVVH ± Di nc h i l d r e nh a sb e e nf a c i l i t a t e db ys i g n i ﬁ c a n t
technological advances leading to increasing popularity of
these methods among pediatric nephrologists and inten-
sivists, while the use of acute PD for children needing ARRT
is declining [4, 11]. However, there is currently no evidence
to support superiority of any speciﬁc ARRT modality in
children with D+HUS.
The outcome data shown in Table 2 illustrates the excel-
lent renal recovery which ultimately occurs in most patients
as previously shown by many investigators [7]. The data also
demonstrates that residual proteinuira is a frequent compli-
cation,suggestingthatthesepatientshavesuﬀeredsigniﬁcant
renal injury with potentially long-term consequences and,
therefore, need careful followup.
This study is limited by its retrospective descriptive
methodology as well as the biased preference for PD in our
center. However,despitethese limitations, we believethatthe
experience reported here represents a worthy addition to the
currently modest body of evidence supporting the use of PD
in children with D+HUS needing ARRT.4 International Journal of Nephrology
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